# Nuclide record opp-grpr-psma-negative-prostate (opportunity). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/opportunities/opp-grpr-psma-negative-prostate/>
  a schema:CreativeWork ;
  nuclide:kind "opportunity" ;
  schema:identifier "opp-grpr-psma-negative-prostate" ;
  schema:name "GRPR imaging when the PSMA scan is negative"@en ;
  schema:alternateName "GRPR PET"@en, "bombesin receptor imaging"@en ;
  schema:description "Prostate cancer imaging and treatment both rely on one protein, PSMA. In a minority of men the tumour does not carry it, and for those men a negative scan is a dead end. A second receptor, GRPR, is the best-studied alternative, and the honest reading of the head-to-head studies is that it finds fewer lesions overall but different ones."@en ;
  schema:url <https://nuclide.cc/opportunities/opp-grpr-psma-negative-prostate/> ;
  schema:dateModified "2026-09-23"^^xsd:date ;
  schema:citation <https://pubmed.ncbi.nlm.nih.gov/38423030/>, <https://pmc.ncbi.nlm.nih.gov/articles/PMC8612333/>, <https://pubmed.ncbi.nlm.nih.gov/31482426/>, <https://clinicaltrials.gov/study/NCT03872778>, <https://jnm.snmjournals.org/content/61/6/792> ;
  nuclide:tag "unmet need first", "prostate", "PSMA-negative", "second-look imaging" ;
  nuclide:related <https://nuclide.cc/isotopes/ga-68/>, <https://nuclide.cc/isotopes/lu-177/> ;
  nuclide:indications <https://nuclide.cc/indications/prostate-mcrpc/>, <https://nuclide.cc/indications/prostate-bcr/> ;
  nuclide:technologies <https://nuclide.cc/technologies/psma-pet/>, <https://nuclide.cc/technologies/pet-ct/>, <https://nuclide.cc/technologies/radioligand-therapy/>, <https://nuclide.cc/technologies/peptide-drug-conjugate/> ;
  nuclide:targets <https://nuclide.cc/targets/grpr/>, <https://nuclide.cc/targets/psma/> .